Table of Contents

Acknowledgments

Chapter 1 Introduction: The Psychedelic Renaissance Continues
Michael Winkelman and Ben Sessa

Part One Psychiatry
Chapter 2 Psychedelics and Psychiatry: A New Treatment Model for the 21st Century
Charles S. Grob and Gary Bravo
Chapter 3 Therapeutic Applications of 3,4-methylenedioxymethamphetamine (MDMA)
Ben Sessa
Chapter 4 Psilocybin Therapy for Major Depressive Disorder
James JH Rucker
Chapter 5 Ketamine Therapy for Treatment-Resistant Depression
L. Alison McInnes and Marc Ettensohn
Chapter 6 Evidence for the Therapeutic Effects of Ayahuasca
Dráulio Barros de Araújo

Part Two Substance Abuse
Chapter 7 Psilocybin for the Treatment of Substance Use Disorders
Ishani Rao and Greg Lydall
Chapter 8 Potential Applications of Cannabis and Cannabinoids in the Treatment of Substance Use Disorder and in Harm Reduction
José Carlos Bouso, Rafael Guimaraes dos Santos, and Jaime Hallak
Chapter 9 Psychedelic Therapy as a Complementary Treatment Approach for Alcohol Use Disorders
Peter Eischens and William Leigh Atherton

Part Three Medical Hypotheses
Chapter 10 Effects of Psychedelics on Inflammation and Immunity
Attila Szabo
Chapter 11 The Protective Role of Dimethyltryptamine against Ischemia-Reperfusion Injury
Ede Frecska, Attila Istvan Kovacs, and Attila Szabo
Chapter 12 Psychedelic Treatment of Disruptive Personality Patterns
Petr Winkler and Rita Kocárová

Part Four Treatment and Training
Chapter 13 Guidelines in Applying Psychedelic Therapies
Friederike Meckel
Chapter 14 Training Psychedelic Therapists
Janis Phelps

Part Five Societal Engagement with Psychedelics
Chapter 15 Community-Based Full-Spectrum Harm Reduction Approaches When Caring for Psychoactive- and Psychedelic-Related Problems at a Transformational Festival
Maria Carmo Carvalho, Cristiana Vale Pires, Ana Luísa Costa, Daniel Martins, Helena Valente, Inês Macedo, Paula Frango, and Raquel Lira
Chapter 16 Microdosing Psychedelics
James Fadiman and Sophia Korb
Chapter 17 Bringing Psychedelics and Entactogens into Mainstream Pharmaceuticals: A Focus on MDMA
Anne C. Wagner, Michael C. Mithoefer, and Rick Doblin

About the Editors and Contributors

Index

Promotional Information

Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psychological, physiological, and social problems.

About the Author

Michael Winkelman, PhD, is retired from the School of Human Evolution and Social Change at Arizona State University, where he served as director of the medical anthropology program.

Ben Sessa, MD, is a consultant child and adolescent psychiatrist working in adult addiction services and with PTSD in veterans.

Reviews

Recommended. All readers.
*Choice*